November 19, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2611913

Assessing Multiple Treatment Regimens for Tuberculosis.

Listen to this summary

This phase 2 randomized trial (PARADIGM4TB) asked whether new four-drug regimens containing ganfeborole and/or BTZ-043 could shorten or improve tuberculosis treatment compared with the standard 24-week HRZE regimen, using early sputum culture clearance (log10 time-to-positivity slope) as the primary measure. Two regimens, ganfeborole-bedaquiline-pretomanid-moxifloxacin (BPMG) and BTZ-043-bedaquiline-delamanid-moxifloxacin (BDMT), showed a posterior probability of superiority over HRZE of 0.83 and 0.99, respectively, with acceptable safety profiles to advance to further evaluation. The results were used to select regimens for further study rather than to establish definitive efficacy.

Hanif Esmail, Nicholas I Paton, Jodie A Schildkraut, Ilaria Motta, Alexander J Szubert, Suzanne M Dufault, Norbert Heinrich, Simon Tiberi, Cissy M Kityo, Timothy D McHugh, Fairoez Ryklief, Daniela M Cirillo, Rodney Dawson, Karen Sanders, Stellah Mpagama, Lindsay C Thompson, Le Hong Van, Dominic Wakerley, Elena Tudor, Angela M Crook, Patrick P J Phillips, Guy Thwaites, Christoph Lange, Martin J Boeree, Gareth Maher-Edwards, Natasa Lazarevic, Jolanda E van de Logt, Derek J Sloan, David Barros-Aguirre, Michael Hoelscher

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play